Analyst firms · BofA Securities · STOK
BofA Securities STOK price target and rating history
Stoke Therapeutics Inc. (STOK) · Health Care
BofA Securities rates Stoke Therapeutics Inc. (STOK) Neutral with a $12 price target, as of its latest action on May 1, 2023. It has published 3 rating actions on STOK since December 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a STOK price target in the last 12 months, the median target is $42.
- Current rating
- Neutral
- Price target
- $12
- Median target, all firms
- $42
- Actions on STOK
- 3
BofA Securities price target on STOK
Every BofA Securities rating on STOK
- May 1, 2023
- Jan 6, 2023
- Dec 3, 2021
How other firms rate STOK
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Goldman Sachs | Buy | $44 | Jul 13, 2026 |
| Wolfe Research | Outperform | $40 | Feb 24, 2026 |
| Guggenheim | Buy | $60 | Feb 5, 2026 |
| Chardan Capital Markets | Buy | $35 | Jan 5, 2026 |
Questions about BofA Securities and STOK
- What is BofA Securities's price target for STOK?
- BofA Securities's latest stated price target for Stoke Therapeutics Inc. (STOK) is $12, from its action on May 1, 2023.
- What is BofA Securities's rating on STOK?
- BofA Securities rates STOK Neutral, a neutral rating, as of May 1, 2023.
- When did BofA Securities last change its view on STOK?
- On May 1, 2023, BofA Securities upgrades to Neutral from Underperform, price target $9 to $12.
- How does BofA Securities's STOK target compare with other analysts?
- Across 4 firms with a STOK price target in the last 12 months, the median target is $42.
All BofA Securities ratingsSTOK news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.